ETS variant transcription factor 6-ABL proto-oncogene 1 fusion protein (ETV6-ABL1) (ETV6-ABL1)

ETV6-ABL1, historically referred to as TEL-ABL, is an oncogenic chimeric fusion protein resulting from the reciprocal chromosomal translocation t(9;12)(q34;p13) (Papadopoulos et al., 1995; PubMed: 7585571). This genetic rearrangement fuses the N-terminal pointed (PNT) oligomerization domain of the ETV6 transcription factor to the C-terminal catalytic domain of the ABL1 non-receptor tyrosine kinase (Golub et al., 1996; PubMed: 8649404). The PNT domain facilitates constitutive oligomerization, which triggers the auto-phosphorylation and continuous activation of the ABL1 kinase domain (Million et al., 2002; PubMed: 12006479). This aberrant activity stimulates multiple oncogenic signaling pathways, including PI3K/AKT, JAK/STAT, and RAS/MAPK, leading to malignant transformation, enhanced cell survival, and uncontrolled proliferation of hematopoietic cells (Cazzaniga et al., 1999; PubMed: 10406752). While rare compared to BCR-ABL1, ETV6-ABL1 is a significant driver in various hematologic malignancies, including chronic myeloid leukemia-like syndromes and acute leukemias (NCBI Gene ID: 2120). Because it retains the same kinase domain as BCR-ABL1, the fusion protein is generally sensitive to tyrosine kinase inhibitors (TKIs) like imatinib and dasatinib, although clinical management is often challenged by the rapid emergence of resistance mutations (Okuda et al., 1996; PubMed: 8634449).

Other names

TEL-ABLTEL-ABL1ETV6-ABLt(9;12)(q34;p13) fusion proteinETS variant transcription factor 6-Abelson murine leukemia viral oncogene homolog 1 fusion

Competitive inhibition of the ATP-binding site within the ABL1 kinase domain, which prevents the phosphorylation of downstream effector substrates and halts oncogenic signaling (Million et al., 2002; PubMed: 12006479).